Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24649163)

1.

Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab.

Tanaka T, Ichikawa K, Maruoka T, Tomita S, Ueda H, Yamaguchi T, Shida Y, Kato H, Nagata H, Kubota K, Akimoto N, Sakamoto C, Imura J, Arita M, Tanaka H, Okamoto Y, Igarashi Y, Fujimori T.

Mol Clin Oncol. 2013 Mar;1(2):291-296. Epub 2013 Jan 10.

2.

Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.

Kim KM, Lee EJ, Ha S, Kang SY, Jang KT, Park CK, Kim JY, Kim YH, Chang DK, Odze RD.

Am J Surg Pathol. 2011 Sep;35(9):1274-86. doi: 10.1097/PAS.0b013e318224cd2e.

PMID:
21836485
3.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

4.
5.

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S.

Ann Oncol. 2012 Jul;23(7):1706-12. doi: 10.1093/annonc/mdr558. Epub 2011 Nov 23.

6.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

8.

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G.

Clin Cancer Res. 2011 Oct 15;17(20):6531-41. doi: 10.1158/1078-0432.CCR-10-3376. Epub 2011 Sep 2.

9.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.

Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK.

Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.

10.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ.

J Clin Oncol. 2007 Aug 1;25(22):3230-7.

11.
12.

[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].

Tímár J, Láng I.

Magy Onkol. 2008 Jun;52(2):185-91. doi: 10.1556/MOnkol.52.2008.2.7. Review. Hungarian.

PMID:
18640895
13.

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.

Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S.

BMC Cancer. 2009 Aug 27;9:303. doi: 10.1186/1471-2407-9-303.

14.

Metachronous serrated neoplasia is uncommon after right colectomy in patients with methylator colon cancers with a high degree of microsatellite instability.

Messick CA, Kravochuck S, Church JM, Kalady MF.

Dis Colon Rectum. 2014 Jan;57(1):39-46. doi: 10.1097/01.dcr.0000437690.18709.76.

PMID:
24316944
15.

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.

Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.

Oncology. 2010;79(5-6):415-22. doi: 10.1159/000323279. Epub 2011 Apr 7.

PMID:
21474966
16.

K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues.

Monstein HJ, Fransén K, Dimberg J, Söderkvist P.

Eur J Clin Invest. 2004 Feb;34(2):100-6.

PMID:
14764072
17.
18.

Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.

Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A.

Int J Cancer. 2010 Jul 15;127(2):367-80. doi: 10.1002/ijc.25042.

PMID:
19908233
19.

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Clin Cancer Res. 2008 Dec 1;14(23):7884-95. doi: 10.1158/1078-0432.CCR-07-5165.

20.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk